Lea in Medical Technology

American Legion Anticipates Institute of Medicine Report on Gulf War Veterans

...ops during the 1991 Gulf War. These include, most prominently, a group of chemical neurotoxins to which many veterans were exposed. According to Dr. lea Steele, Scientific Director of the federal Research Advisory Committee on Gulf War Veterans' Illnesses, "In years past, it was common for government o...

Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds

...ke no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. CONTACT: Leiv lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc. Web site:

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors

...ke no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. CONTACT: Leiv lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc. Web site:

Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting

...//www.pharmacyclics.com . Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc. CONTACT: Leiv lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc. Web site:

Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer

...ke no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. CONTACT: Leiv lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, Inc., +1-415-225-5050, forPharmacyclics, Inc. Web site:

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

...ke no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. CONTACT: Leiv lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, Inc., +1-415-225-5050, forPharmacyclics, Inc. Web site: